8-K: Odyssey Health Secures $100K Loan, Issues Warrants

Odyssey Health, Inc. has secured a $100,000 promissory note with an 18% interest rate and issued 100,000 common stock warrants to a private investor.

Summary

• Odyssey Health, Inc. (ODYY) entered into a Promissory Note Agreement for $100,000 with Peter D'Arruda, an accredited private investor.
• The promissory note bears an interest rate of eighteen percent (18%) per annum.
• The entire outstanding loan amount and accrued interest are due in full on September 30, 2026.
• The company issued a warrant to the investor to purchase 100,000 shares of Odyssey common stock at an exercise price of $0.10 per share.
• The warrant is exercisable for five years and one day from its issue date of October 1, 2025.
• The note becomes immediately due and payable upon the company's insolvency, bankruptcy, general assignment for creditors, filing of a petition in bankruptcy, or appointment of a receiver or trustee.

Sentiment

Score: 3

Explanation: The company secured needed capital, which is a positive for immediate liquidity. However, the very high 18% interest rate and the issuance of warrants suggest a challenging financing environment and potential future dilution, which significantly temper the positive impact of the capital raise.

Positives

• Secured $100,000 in capital, providing immediate liquidity for operations.
• The warrant exercise price of $0.10 per share is above the common stock par value of $0.001, indicating potential future cash inflow if exercised.

Negatives

• The 18% annual interest rate on the promissory note is exceptionally high, suggesting a potentially high-risk borrower or limited access to more favorable financing options.
• The issuance of 100,000 warrants could lead to dilution for existing shareholders if exercised, impacting per-share value.
• The relatively small loan amount of $100,000, coupled with the high interest rate, suggests it may be for short-term operational needs rather than significant growth initiatives.

Risks

• High interest expense (18% per annum) will significantly impact the company's profitability and cash flow over the next year.
• Potential dilution of existing shareholders' equity if the 100,000 warrants are exercised.
• The acceleration clause in the promissory note, making the loan immediately due upon events like insolvency or bankruptcy, poses a significant liquidity risk if the company's financial health deteriorates.
• Reliance on private, high-interest debt may signal challenges in securing more conventional or favorable financing, indicating underlying financial vulnerabilities.

Future Outlook

The filing does not provide explicit forward-looking statements or guidance regarding future financial performance, strategic initiatives, or operational outlook beyond the terms of the debt and warrant agreements.

Management Comments

• Joseph Michael Redmond, President and CEO, signed the Promissory Note and Warrant on behalf of Odyssey Health, Inc.

Industry Context

This financing event is characteristic of smaller, emerging growth companies that may have limited access to traditional bank financing. Such companies often rely on private investors for capital, frequently at higher interest rates and with equity sweeteners like warrants, reflecting a higher risk profile compared to more established entities.

Comparison to Industry Standards

• An 18% annual interest rate is significantly higher than typical commercial bank loans or corporate bonds for established companies, which usually range from 4-8% depending on creditworthiness and market conditions. This suggests Odyssey Health, Inc. faces a higher cost of capital, potentially due to its stage of development, perceived risk, or limited financial history.
• The inclusion of warrants as an equity sweetener is common in private financing for early-stage or higher-risk companies, but the specific terms (100,000 shares at $0.10) would need to be compared against similar-sized companies in the health or biotech sector to assess market standard dilution.

Stakeholder Impact

• Shareholders: Face potential dilution if the warrants are exercised, but the capital infusion could support operations and prevent more severe financing options.
• Creditors: The new debt adds to the company's liabilities, but the capital could improve short-term solvency, potentially benefiting other creditors.
• Employees: Improved short-term liquidity may help ensure continued operations and payroll, reducing immediate job insecurity.

Next Steps

• Repayment of the $100,000 promissory note plus 18% interest by the maturity date of September 30, 2026.
• Potential exercise of 100,000 warrants by the investor within five years and one day from October 1, 2025, which would result in additional capital for the company and dilution for existing shareholders.

Key Dates

Recommendation

While the capital infusion provides immediate liquidity, the high 18% interest rate on the $100,000 promissory note signals significant financial risk or limited access to more favorable financing. The issuance of warrants also introduces potential future dilution. Investors should hold to monitor how this capital is deployed and if the company can secure more sustainable, lower-cost financing in the future, as the current terms suggest underlying challenges that could impact long-term shareholder value.

Keywords

Odyssey Health, ODYY, Promissory Note, Warrant, Debt Financing, Equity Dilution, High Interest Loan, Private Placement, SEC Filing, 8-K